Drug Survival Associated With Effectiveness and Safety of Treatment With Guselkumab, Ixekizumab, Secukinumab, Ustekinumab, and Adalimumab in Patients With Psoriasis

by | Jul 6, 2022 | Publications | 0 comments

JAMA Dermatol, 2022.

Yiu ZZN, Becher G, Kirby B, Laws P, Reynolds NJ, Smith CH, Warren RB, Griffiths CEM; BADBIR Study Group.

Read publication: JAMA Dermatol

0 Comments

Related